These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 18765397)

  • 1. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
    Serruys PW; García-García HM; Buszman P; Erne P; Verheye S; Aschermann M; Duckers H; Bleie O; Dudek D; Bøtker HE; von Birgelen C; D'Amico D; Hutchinson T; Zambanini A; Mastik F; van Es GA; van der Steen AF; Vince DG; Ganz P; Hamm CW; Wijns W; Zalewski A;
    Circulation; 2008 Sep; 118(11):1172-82. PubMed ID: 18765397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
    White H; Held C; Stewart R; Watson D; Harrington R; Budaj A; Steg PG; Cannon CP; Krug-Gourley S; Wittes J; Trivedi T; Tarka E; Wallentin L
    Am Heart J; 2010 Oct; 160(4):655-61. PubMed ID: 20934559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darapladib.
    Bui QT; Wilensky RL
    Expert Opin Investig Drugs; 2010 Jan; 19(1):161-8. PubMed ID: 20001561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?
    Boekholdt SM; de Winter RJ; Kastelein JJ
    Circulation; 2008 Sep; 118(11):1120-2. PubMed ID: 18779454
    [No Abstract]   [Full Text] [Related]  

  • 6. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
    Riley RF; Corson MA
    IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darapladib: an emerging therapy for atherosclerosis.
    Corson MA
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):241-8. PubMed ID: 20660537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral artery disease, biomarkers, and darapladib.
    Berger JS; Ballantyne CM; Davidson MH; Johnson JL; Tarka EA; Lawrence D; Trivedi T; Zalewski A; Mohler ER
    Am Heart J; 2011 May; 161(5):972-8. PubMed ID: 21570531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
    Packard CJ
    Curr Opin Cardiol; 2009 Jul; 24(4):358-63. PubMed ID: 19417639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darapladib for preventing ischemic events in stable coronary heart disease.
    ; White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D; Armstrong PW; Avezum A; Aylward PE; Bryce A; Chen H; Chen MF; Corbalan R; Dalby AJ; Danchin N; De Winter RJ; Denchev S; Diaz R; Elisaf M; Flather MD; Goudev AR; Granger CB; Grinfeld L; Hochman JS; Husted S; Kim HS; Koenig W; Linhart A; Lonn E; López-Sendón J; Manolis AJ; Mohler ER; Nicolau JC; Pais P; Parkhomenko A; Pedersen TR; Pella D; Ramos-Corrales MA; Ruda M; Sereg M; Siddique S; Sinnaeve P; Smith P; Sritara P; Swart HP; Sy RG; Teramoto T; Tse HF; Watson D; Weaver WD; Weiss R; Viigimaa M; Vinereanu D; Zhu J; Cannon CP; Wallentin L
    N Engl J Med; 2014 May; 370(18):1702-11. PubMed ID: 24678955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic inhibition of lipoprotein-associated phospholipase A
    Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
    Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.
    Choi WG; Prasad M; Lennon R; Gulati R; Prasad A; Lerman LO; Lerman A
    Coron Artery Dis; 2018 Mar; 29(2):104-113. PubMed ID: 29135482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
    Wilensky RL; Shi Y; Mohler ER; Hamamdzic D; Burgert ME; Li J; Postle A; Fenning RS; Bollinger JG; Hoffman BE; Pelchovitz DJ; Yang J; Mirabile RC; Webb CL; Zhang L; Zhang P; Gelb MH; Walker MC; Zalewski A; Macphee CH
    Nat Med; 2008 Oct; 14(10):1059-66. PubMed ID: 18806801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2.
    Zhang H; Zhang JY; Sun TW; Shen DL; He F; Dang YH; Li L
    Clin Invest Med; 2013 Feb; 36(1):E32-41. PubMed ID: 23374598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
    O'Donoghue ML; Braunwald E; White HD; Serruys P; Steg PG; Hochman J; Maggioni AP; Bode C; Weaver D; Johnson JL; Cicconetti G; Lukas MA; Tarka E; Cannon CP
    Am Heart J; 2011 Oct; 162(4):613-619.e1. PubMed ID: 21982651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients.
    Muzzio ML; Miksztowicz V; Brites F; Aguilar D; Repetto EM; Wikinski R; Tavella M; Schreier L; Berg GA
    Arch Med Res; 2009 Jan; 40(1):48-53. PubMed ID: 19064127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.
    Stewart RA; White HD
    Curr Atheroscler Rep; 2011 Apr; 13(2):132-7. PubMed ID: 21207201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Lp-PLA2 in lipid-lowering therapy.
    Racherla S; Arora R
    Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis.
    García-García HM; Klauss V; Gonzalo N; Garg S; Onuma Y; Hamm CW; Wijns W; Shannon J; Serruys PW
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):695-703. PubMed ID: 21594650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
    O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
    JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.